SEC Form 4 · accession 0001093557-19-000063
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin R Sayer
Officer — President, CEO and Chairman · Director
Period of report
Mar 8, 2019
Accepted (ET)
Mar 11, 2019 · 8:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 8, 2019 | A | 35,829 | $0.001 | A | 344,666 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.
- F2Included in this number are 116,618 unvested restricted stock units, 35,829 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 53,696 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 27,093 of which were granted on March 8, 2017 and shall vest through March 8, 2020.